25 February 2011
Relationship between pro-anti-inflammatory cytokines, T-cell activation and CA 125 in obese patients with heart failure
Nadia M. HamdyDOI: 10.12659/MSM.881453
Med Sci Monit 2011; 17(3): CR174-179
Abstract
Background: This researcher previously found that serum levels of some inflammatory cytokines are elevated in patients with cardiovascular disease (CVD). Hence, this study investigated the relationship between circulating levels of pro-anti-inflammatory cytokines, T-cell activation marker and carbohydrate antigen 125 (CA 125) for the first time in obese Egyptian patients with heart failure (HF).
Material/Methods: This study included 60 HF patients, and 30 normal controls, with age range 50–70 years. HF patients were divided into 2 groups: non-obese mild HF according to clinical status (New York Heart Association Class) (NYHA class I/II) (n =20) and obese severe HF (NYHA class III/IV) (n=40). Serum pro-anti-inflammatory cytokine levels (TNF-α, IL-6, and IL-10), T-cell activation marker (sIL-2R/CD25), and CA 125; tumor marker were measured by ELISA.
Results: Serum levels of TNF-α, IL-6, and IL-10 as pro-anti-inflammatory cytokines, sIL-2R/CD25 as T-cell activation marker, and CA 125 as tumor marker were significantly higher in HF patients than in normal controls. Moreover, serum levels of TNF-α, IL-6, sIL-2R/CD25, and IL-10, as well as CA 125 were significantly higher in the obese than in the non-obese mild HF patients. Correlation analysis showed that CA 125 was positively related to BMI, TNF-α, IL-6, and sIL-2R/CD25 in the HF patients group.
Conclusions: These findings show that CA 125 is markedly elevated in HF patients, and is correlated with serum TNF-α, IL-6, and sIL-2R/CD25 levels. Therefore, we can conclude that CA125, being a tumor marker, is closely related to the cytokine system.
Keywords: Lymphocyte Activation - immunology, Inflammation Mediators - blood, Hemodynamics, Heart Failure - physiopathology, Cytokines - blood, Case-Control Studies, CA-125 Antigen - blood, Obesity - immunology, T-Lymphocytes - immunology
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952